Newsroom

For media inquiries, please contact 340B Health Senior Vice President of Communications Jon Tilton at jon.tilton@340bhealth.org​​​​​​​ or 202-536-2285.

• 340B HEALTH BOARD ELECTS THREE NEW MEMBERS

  May 25, 2022 in 340B Health News Releases

• FIVE HOSPITAL ASSOCIATIONS URGE APPEALS COURTS TO BACK 340B ENFORCEMENT

  May 17, 2022 in 340B Health News Releases

• FINANCIAL LOSSES FROM DRUG COMPANIES’ 340B RESTRICTIONS HAVE MORE THAN DOUBLED SINCE THE END OF 2021

  May 05, 2022 in 340B Health News Releases

• STATEMENT ON GOVERNMENT APPEAL OF COURT DECISION IN ASTRAZENECA 340B CONTRACT PHARMACY LAWSUIT

  April 13, 2022 in 340B Health News Releases

• STUDY DEMONSTRATES ESSENTIAL ROLE OF 340B AMID COVID-19 CHALLENGES AND DRUG COMPANY RESTRICTIONS

  April 07, 2022 in 340B Health News Releases

• BOEHRINGER INGELHEIM REFERRED FOR PENALTIES FOR CONTINUED VIOLATIONS OF FEDERAL LAW ON 340B PRICING

  March 29, 2022 in 340B Health News Releases

• Hospital groups worry as more drugmakers limit 340B discounts

  March 25, 2022 in 340B in the News

• STATEMENT ON JOHNSON & JOHNSON RESTRICTING 340B DISCOUNTS

  March 21, 2022 in 340B Health News Releases

• STATEMENT ON GILEAD RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES

  March 16, 2022 in 340B Health News Releases

• STATEMENT ON APPROVAL OF 340B ELIGIBILITY PROTECTIONS FOR SAFETY-NET HOSPITALS ON THE COVID FRONT LINES

  March 11, 2022 in 340B Health News Releases

• STATEMENT ON NEW DIRECTOR OF HRSA OFFICE OF PHARMACY AFFAIRS

  February 28, 2022 in 340B Health News Releases

• STATEMENT ON FEDERAL COURT DECISION IN ASTRAZENECA’S 340B COMMUNITY PHARMACY LAWSUIT

  February 16, 2022 in 340B Health News Releases